drugset / Trial / NCT03336606
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Phase 1
Completed
13 enrolled
Providence Health & Services
MedImmune LLC · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.
Timeline
- Start
- 2018-07-25
- Primary completion
- 2025-06-12
- Completion
- 2026-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TAVOLIMAB | Monoclonal antibody | 30 mg | — |
| Comparator | TAVOLIMAB | Monoclonal antibody | 90 mg | — |